| P/E (FY) | — | Sales (TTM) | $1.4M |
| Earnings (TTM) | -$1.8M | ROE | −125.69% |
| Net Margin | −207.19% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $988,490 | Trading Days | 2142 |
| 52W High | 0.97 |
| 52W Low | 0.15 |
| % Off High | −69.07% |
| YTD | −55.90% | 1Y | −33.33% |
| 3Y | −99.63% | 5Y | −99.99% |
| Since incept. (ann.) | −67.96% |
| Ann. Volatility (1Y) | 204.88% | Ann. Volatility (3Y) | 175.28% |
| Sharpe (1Y) | 0.74 | Sharpe (3Y) | −0.24 |
| Max Drawdown (1Y) | −83.80% | Max Drawdown (3Y) | −99.82% |
| Beta (3Y, vs SPY) | 2.86 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ZVSA | ZyVersa Therapeutics, Inc. | $939,127 | — |
| HEPA | Hepion Pharmaceuticals, Inc. | $1.3M | — |
| PTIX | Protagenic Therapeutics, Inc.\new | $685,993 | — |
| MTNB | Matinas BioPharma Holdings, Inc. | $1.9M | — |
| BPTH | BIO-PATH HOLDINGS, INC. | $2.0M | — |
| ARTL | ARTELO BIOSCIENCES, INC. | $2.1M | — |
| AZTR | Azitra, Inc. | $2.1M | — |
| DCOY | Decoy Therapeutics Inc. | $2.1M | — |
| NXTS | Nexentis Technologies Inc. | $2.2M | — |
| VCNX | VACCINEX, INC. | $2.2M | — |
| OGEN | ORAGENICS INC |
| $2.2M |
| — |
| GRI | GRI Bio, Inc. | $2.5M | — |
